127 results on '"Andriulli, A"'
Search Results
2. Landmarks for dual biological therapy in inflammatory bowel disease: lesson from two case reports of vedolizumab in combination with ustekinumab
3. The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy
4. Common genetic variants associated with pancreatic adenocarcinoma may also modify risk of pancreatic neuroendocrine neoplasms
5. Characteristics and early clinical outcomes of patients undergoing totally subcutaneous vs. transvenous single chamber implantable cardioverter defibrillator placement
6. Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation
7. A different perspective on sofosbuvir‐ledipasvir treatment of patients with HCV genotype 1b cirrhosis: The ital‐c network study
8. Cancer sniffer dogs: how can we translate this peculiarity in laboratory medicine? Results of a pilot study on gastrointestinal cancers
9. Hepatitis C Virus Clearance in Older Adults
10. Influence of universal HBV vaccination on chronic HBV infection in Italy: Results of a cross‐sectional multicenter study
11. Etiological factors of chronic hepatitis in Italy: a 2014 national survey
12. Etiological factors of chronic hepatitis in Italy: a 2014 national survey
13. The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar
14. P621 Efficacy and safety of golimumab in ulcerative colitis. Preliminary data from a multicenter Italian study
15. P117 Functional implications of microRNAs in Crohnʼs disease revealed by integrating microRNA and messenger RNA expression profiling
16. OP005 The PROSIT cohort of infliximab biosimilar in IBD: a prolonged follow-up on the efficacy and safety across Italy
17. Letter: HBsAg kinetics-guided interferon therapy for chronic hepatitis D - authorsʼ reply
18. The impact of infection by multidrug‐resistant agents in patients with cirrhosis. A multicenter prospective study
19. Variation in genes encoding for interferon λ-3 and λ-4 in the prediction of HCV-1 treatment-induced viral clearance
20. Letter: cytomegalovirus colitis in a patient treated with ipilimumab for metastatic melanoma
21. Atrial Tachyarrhythmias Temporally Precede Fluid Accumulation in Implantable Device Patients
22. Advance in molecular diagnostic tools for hepatitis B virus detection
23. Long-term outcome of hepatitis B virus-related Chronic Hepatitis under protracted nucleos(t)ide analogues
24. Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B
25. Randomised clinical trial: low-volume bowel preparation for colonoscopy - a comparison between two different PEG-based formulations
26. Eltrombopag before Procedures in Patients with Cirrhosis and Thrombocytopenia
27. Epidemiology and diagnosis of hepatitis D virus
28. DNA Methyltransferases 1 and 3b Expression in Huh-7 Cells Expressing HCV Core Protein of Different Genotypes
29. Unawareness of HBV infection among inpatients in a Southern Italian hospital
30. Identification and surveillance of 19 Lynch syndrome families in southern Italy: report of six novel germline mutations and a common founder mutation
31. Long-Term Outcome After Antiviral Therapy of Patients With Hepatitis C Virus Infection and Decompensated Cirrhosis
32. Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg-interferon α-2b and ribavirin
33. Tailoring the length of antiviral treatment for hepatitis C
34. TNF-α Polymorphisms in Primary Biliary Cirrhosis: A Northern and Southern Italian Experience
35. Sustained virological responses following standard anti-viral therapy in decompensated HCV-infected cirrhotic patients
36. Proton Pump Inhibitors After Endoscopy in Peptic Ulcer Bleeding
37. Radiofrequency Thermal Ablation vs. Percutaneous Ethanol Injection for Small Hepatocellular Carcinoma in Cirrhosis: Meta-Analysis of Randomized Controlled Trials
38. Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection#
39. Early discontinuation of ribavirin in HCV-2 and HCV-3 patients responding to Peg-interferon alpha-2a and ribavirin
40. Polymorphism of the IRGM Gene Might Predispose to Fistulizing Behavior in Crohnʼs Disease
41. High- Versus Low-Dose Proton Pump Inhibitors After Endoscopic Hemostasis in Patients With Peptic Ulcer Bleeding: A Multicentre, Randomized Study
42. Erythrocyte-Mediated Delivery of Dexamethasone in Patients With Mild-to-Moderate Ulcerative Colitis, Refractory to Mesalamine: A Randomized, Controlled Study
43. Reply
44. Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis
45. Risk of Post–Endoscopic Retrograde Cholangiopancreatography Pancreatitis and Ways to Prevent It: Old Myths, a Current Need? The Case of Allopurinol
46. The association of MYO9B gene in Italian patients with inflammatory bowel diseases
47. The Range of ERCP Complications
48. Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial
49. Peginterferon Alfa-2a and Ribavirin for 16 or 24 Weeks in HCV
50. Sequential evaluation of thiopurine methyltransferase, inosine triphosphate pyrophosphatase, and HPRT1 genes polymorphisms to explain thiopurinesʼ toxicity and efficacy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.